Shares of Ocera Therapeutics Inc. (NASDAQ:OCRX) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus target price of $10.67 for the company and are forecasting that the company will post ($0.36) EPS for the current quarter, according to Zacks. Zacks has also given Ocera Therapeutics an industry rank of 102 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research raised shares of Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Tuesday, August 9th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/analysts-anticipate-ocera-therapeutics-inc-nasdaqocrx-to-announce-0-36-eps.html

A number of institutional investors have recently modified their holdings of the company. VHCP Management II LLC acquired a new position in shares of Ocera Therapeutics during the first quarter worth about $2,788,000. Renaissance Technologies LLC boosted its position in shares of Ocera Therapeutics by 39.3% in the first quarter. Renaissance Technologies LLC now owns 146,400 shares of the biopharmaceutical company’s stock worth $430,000 after buying an additional 41,300 shares in the last quarter. Sabby Management LLC boosted its position in shares of Ocera Therapeutics by 3.6% in the first quarter. Sabby Management LLC now owns 399,035 shares of the biopharmaceutical company’s stock worth $1,173,000 after buying an additional 13,735 shares in the last quarter. Vivo Capital LLC acquired a new position in shares of Ocera Therapeutics during the first quarter worth about $451,000. Finally, Deerfield Management Co. acquired a new position in shares of Ocera Therapeutics during the first quarter worth about $221,000. 36.03% of the stock is currently owned by hedge funds and other institutional investors.

Ocera Therapeutics (NASDAQ:OCRX) traded up 3.136% during trading on Wednesday, reaching $2.434. The company’s stock had a trading volume of 13,732 shares. The firm has a 50 day moving average of $2.41 and a 200 day moving average of $2.64. Ocera Therapeutics has a 52 week low of $1.76 and a 52 week high of $4.57. The stock’s market capitalization is $53.19 million.

Ocera Therapeutics (NASDAQ:OCRX) last announced its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.02. Ocera Therapeutics had a negative return on equity of 97.93% and a negative net margin of 23,955.08%. Analysts expect that Ocera Therapeutics will post ($1.34) EPS for the current year.

About Ocera Therapeutics

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

5 Day Chart for NASDAQ:OCRX

Get a free copy of the Zacks research report on Ocera Therapeutics (OCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.